Moderna stock crashes as leaked melanoma data threatens its record August rally - Yahoo Finance
π Moderna stock fell as much as 26% intraday and closed down more than 17%, marking its worst day since August 20.
π° More than $17 billion in market value vanished from Moderna's valuation following the early leak of trial results.
π¬ The leaked data shows the personalized melanoma vaccine combined with Merck's Keytruda cut cancer recurrence or death risk by 42%.
π Moderna shares had nearly quadrupled from mid-August to Wednesday, prompting a profit-taking sell-off before official results.
π― Investors are now focused on Saturday's full data release, particularly performance metrics for lower-risk patients.
π₯ Merck confirmed the early leak of results but noted the vaccine remains central to Moderna's business strategy.
Bullish Signals
- The leaked trial data indicates the personalized melanoma vaccine paired with Merck's Keytruda reduced the risk of cancer recurrence or death by 42%.
- An earlier, smaller trial previously demonstrated a 49% reduction in risk, though it utilized a different patient population.
Risk Factors
- Moderna stock fell as much as 26% intraday and closed down more than 17%, marking its worst trading day since August 20.
- More than $17 billion in market value vanished from the company's valuation following the early leak of trial results ahead of the official conference.
Full Analysis
Moderna (MRNA) stock experienced a significant intraday decline of up to 26% and closed down more than 17%, marking its worst trading day since August 20. This sharp drop occurred after leaked data from a late-stage melanoma vaccine trial circulated ahead of the official results presentation at Europe's major cancer conference in Madrid.
The personalized mRNA vaccine, developed in partnership with Merck (MRK) and paired with Merck's Keytruda immunotherapy drug, reportedly reduced the risk of cancer recurrence or death by 42% in the latest trial data. While these clinical results remain positive, the stock had already rallied nearly fourfold since mid-August following initial trial success, leading to a sell-off as investors took profits before the official data release.
Despite the volatility, the broader healthcare sector saw mixed reactions with competitors like Eli Lilly and Pfizer rising. Analysts are now closely watching the full data set released on Saturday, specifically focusing on outcomes for lower-risk patient populations, which could further influence investor sentiment regarding the vaccine's overall efficacy and commercial potential.